Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OPT-CHF
NCT00063687Phase 3Completed
- Sponsor
- ADVANZ PHARMA
- Start
- Mar 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in heart failure (HF) comparing Oxypurinol Arm with Placebo Arm (2 arms). Primary endpoint: Composite Clinical Endpoint (Clinical Status) at 24 weeks. Started Mar 2003; status: completed.
02
Drugs
oxypurinol
03
Conditions
heart failure (HF)
Beyond the preview
Go deeper on NCT00063687.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063687.